About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

A Leader in Personalised Healthcare

**PHARMACEUTICALS**
- 4 FDA BREAKTHROUGH THERAPY DESIGNATIONS granted for Roche medicines in 2019
- 63 MILLION PATIENTS treated with Roche medicines
- 32 ROCHE MEDICINES on the WHO list of Essential Medicines
- 283 THOUSAND PATIENTS participated in clinical trials

**DIAGNOSTICS**
- 21 BILLION TESTS conducted in 2019 with Roche instruments worldwide
- 9 KEY PRODUCT LAUNCHES for Roche diagnostics in 2019

**INDUSTRY LEADERSHIP**
- #1 in biotechnology, oncology & in vitro diagnostics market
- 11 YEARS RUNNING Roche ranked one of the most sustainable healthcare companies by the Dow Jones Sustainability Indices
- 97,735 EMPLOYEES
- 100+ COUNTRIES

Contact Information
Investor Relations
F. Hoffmann-La Roche Ltd.
CH-4070 Basel
Switzerland
Email: investor.relations@roche.com
Website: www.roche.com/investors

Additional Information
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as "believes", "expects", "anticipates", "projects", "intends", "should", "seeks", "estimates", "future" or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products, increased government pricing pressures, interruptions in production, loss of or inability to obtain adequate protection for intellectual property rights, litigation, loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Website: www.roche.com
Overview of Our Financials

2019 ROCHE GROUP

61.5 CHF BILLION IN SALES
(PHARMACEUTICALS AND DIAGNOSTICS)

22.5 CHF BILLION IN CORE OPERATING PROFIT

11.7 CHF BILLION IN R&D CORE INVESTMENT

33 years IN A ROW OF INCREASED DIVIDENDS*

OVERALL NET SALES FIGURES
SALES BY BUSINESS AREAS FOR PHARMACEUTICALS AND DIAGNOSTICS FOR THE PAST THREE YEARS

CHF TOTAL BILLIONS

2017 2018 2019

PHARMACEUTICALS
41.2 46.0 48.5

DIAGNOSTICS
12.1 12.9 13.0

TOTAL
53.3 56.8 61.5

RESEARCH & DEVELOPMENT

CHF TOTAL BILLIONS

2019 11.7
2018 11.0
2017 10.4

CORE OPERATING PROFIT

CHF TOTAL BILLIONS

2019 22.5
2018 20.5
2017 19.0

CORE EARNINGS PER SHARE

CHF TOTAL BILLIONS

2019 20.16
2018 18.14
2017 15.34

OPERATING FREE CASH FLOW

CHF TOTAL BILLIONS

2019 20.9
2018 18.7
2017 17.8

SHARING OUR SUCCESS WITH INVESTORS

GROSS DIVIDEND FOR ROCHE - ROG.SW

5-YEAR DIVIDEND HISTORY

DIVIDEND PER SHARE

ROG.SW CHF

2019 9.00
2018 8.70
2017 8.30
2016 8.20
2015 8.10

*2019 dividend as proposed by the Board of Directors.
Note: For 1995 a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996.

Our Pharmaceutical Successes

All 10 of the Roche Group’s top 10 selling pharmaceuticals are blockbusters that have sales of more than 1B CHF per year. All of these 10 blockbusters are biotechnology products.
The Roche Group also currently has one of the strongest pharmaceutical development pipelines in the industry, with biotechnology products accounting for a significant part of all projects.
For more information, visit: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm.

ROCHE PHARMACEUTICAL PRODUCTS

In 2019, global sales of the Roche Group’s top five pharmaceutical products were:

<table>
<thead>
<tr>
<th>Product</th>
<th>Sales (CHF)</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin</td>
<td>7.07</td>
<td>+4%</td>
</tr>
<tr>
<td>MabThera/Rituxan</td>
<td>6.48</td>
<td>-4%</td>
</tr>
<tr>
<td>Herceptin</td>
<td>6.04</td>
<td>-12%</td>
</tr>
<tr>
<td>Ocrevus</td>
<td>3.71</td>
<td>+57%</td>
</tr>
<tr>
<td>Perjeta</td>
<td>3.52</td>
<td>+29%</td>
</tr>
</tbody>
</table>

ROCHE PHARMACEUTICAL PIPELINE*

In 2019, the Roche Group’s pharmaceutical pipeline included:

- 72 NEW POTENTIAL MEDICINES
- 26 ONCOLOGY
- 11 IMMUNOLOGY
- 7 INFECTIOUS DISEASES
- 7 OPTHALMOLOGY
- 14 NEUROSCIENCE
- 1 METABOLISM
- 6 OTHERS

- 66 ADDITIONAL INDICATIONS FOR EXISTING MEDICINES
- 39 PHASE III PROJECTS
- 11 PROJECTS CURRENTLY IN REGISTRATION

* status as of 30 January 2020

Copyright © 01 February 2020 by Roche Investor Relations North America, South San Francisco.